Two committees of the US Food & Drug Administration are to look at the use of Elan's Tysabri drug for the treatment of Crohn's disease on July 31.
Elan and its partner Biogen submitted their application late last year. Crohn's is a chronic and progressive inflammatory disease of the gastrointestinal tract, which affects around a million people worldwide.
10,000 people are currently being treated with Tysabri for multiple sclerosis.
